(NASDAQ: RNTX) Rein Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.28%.
Rein Therapeutics's earnings in 2026 is -$50,208,000.On average, 3 Wall Street analysts forecast RNTX's earnings for 2026 to be -$142,217,195, with the lowest RNTX earnings forecast at -$136,640,050, and the highest RNTX earnings forecast at -$146,400,053. On average, 3 Wall Street analysts forecast RNTX's earnings for 2027 to be -$116,042,251, with the lowest RNTX earnings forecast at -$111,491,574, and the highest RNTX earnings forecast at -$119,455,258.
In 2028, RNTX is forecast to generate -$127,384,726 in earnings, with the lowest earnings forecast at -$122,389,247 and the highest earnings forecast at -$131,131,336.